TGF-β resulted to be the principal mediator involved in this switching of NK phenotype suggesting that the use of antibodies targeting TGF-β and its receptors may offer a promising strategy for cancer immunotherapy inhibiting the conversion of NK cells into ILC1s. Here, TGFB1 is linked to cancer.